Abstract 928P
Background
The prediction of early response in locally advanced nasopharyngeal carcinoma (LA-NPC) after concurrent chemoradiotherapy (CCRT) is indeed important for determining the need for timely consolidation therapy. Radiomics has helped medical imaging expand from diagnostic to a personalized clinical decision aid, while most traditional radiomics primarily focus on mono-sequence. Recently, multi-MR sequences model has shown better outcomes in the management of many cancers. However, the validation of a radiomic analysis of multi-MR sequences based on machine learning for this purpose is currently lacking for patients with LA-NPC after CCRT.
Methods
This study comprised 104 patients with LA-NPC, of which 70% were allocated for training and the remaining 30% were used for internal validation. We extracted radiomics features corresponding to each mono-sequences (T1, T1C, T2, DWI, and ADC), and then applied LASSO for feature selection and constructed the risk model using machine learning algorithms including SVM, Random Forest, ExtraTrees, XGBoost and LightGBM. Performance comparisons were made between mono-sequences and then feature fusion was performed to construct a multi-MR sequences model. Clinical features were numerically mapped and analyzed using machine learning algorithms similar to those in the Radiomics Model. Finally, we created a combined model that integrated the radiomics and clinical models to enhance clinical relevance, whose diagnostic effectiveness was evaluated using receiver operator characteristic (ROC) curves in the test cohort.
Results
In the training cohort, while the Clinic model achieved an Area Under the Curve (AUC) of 0.892 and the Fusion model reached 0.972, the Combined model excelled with an AUC of 0.990. Similarly, in the test cohort, the Combined model outperformed both the Clinic (AUC: 0.852) and Fusion models (AUC: 0.886), achieving an AUC of 0.900.
Conclusions
As a result, a combined model, which merges clinical and multi-MR sequences radiomics model, showed good performance for predicting early response of LA-NPC after CCRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Province Entrepreneurship and Innovation Doctoral Talent Program and Jiangsu Province People's Hospital Clinical Capability Enhancement Project.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1025P - Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Presenter: Santeri Pakola
Session: Poster session 03
1026P - Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03
1027P - First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study
Presenter: Marc Oliva Bernal
Session: Poster session 03
1028P - A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms
Presenter: Shuhang Wang
Session: Poster session 03
Resources:
Abstract
1029P - Preclinical development of TCR-modified T cell therapies against mutated KRAS
Presenter: Hugh Salter
Session: Poster session 03
1030P - Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review
Presenter: Lorena Escalante Romero
Session: Poster session 03
1032P - Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activity
Presenter: Patrick Innamarato
Session: Poster session 03
1033P - Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumors
Presenter: Zhihong Huang
Session: Poster session 03
1034P - Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patients
Presenter: Mingyu Liu
Session: Poster session 03
1035P - A new IL-6 inducing mechanism in cancer with new therapeutic possibilities
Presenter: Leif Håkansson
Session: Poster session 03